Professor Arun Sanyal
Professor Pierre Bedossa
Professor Quentin Anstee
| A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis | 2024 |
|
Professor Fiona Oakley
Dr Simon Cockell
Dr Olivier Govaere
Professor Ann Daly
Professor Arun Sanyal
et al. | An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD) | 2024 |
|
Professor Quentin Anstee
Professor Arun Sanyal
| NIS2+TM as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials | 2024 |
|
Professor Arun Sanyal
Professor Quentin Anstee
| Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis | 2023 |
|
Professor Cliff Brass
Professor Arun Sanyal
Professor Quentin Anstee
| Validation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis | 2023 |
|
Professor Arun Sanyal
Professor Quentin Anstee
| Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis | 2022 |
|
Dr Marie Boyle
Professor Stuart McPherson
Professor Arun Sanyal
Professor Quentin Anstee
| Letter: non-invasive prediction models to exclude cirrhosis in NAFLD—not everyone fits the mould. Authors' reply | 2022 |
|
Professor Quentin Anstee
Professor Arun Sanyal
| Noninvasive Evaluation of Response to Obeticholic Acid in Patients with NASH: Results from the REGENERATE Study | 2022 |
|
Professor Helen Reeves
Professor Arun Sanyal
| Corrigendum to ‘Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis’ [J Hepatol 75 (2021) 865–878] | 2021 |
|
Professor Quentin Anstee
Professor Arun Sanyal
| Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study | 2021 |
|
Dr Catherine Willoughby
Professor Helen Reeves
Professor Arun Sanyal
| Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis | 2021 |
|
Professor Pierre Bedossa
Professor Quentin Anstee
Professor Arun Sanyal
| A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study | 2020 |
|
Professor Arun Sanyal
Professor Quentin Anstee
| A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial | 2020 |
|
Dr Matthew Breckons
Dr Yemi Oluboyede
Professor Luke Vale
Professor Laura Ternent
Professor Arun Sanyal
et al. | Evaluating the patient-perceived impact of non-alcoholic steatohepatitis with compensated cirrhosis | 2020 |
|
Dr Lorraine McSweeney
Dr Matthew Breckons
Dr Gulnar Fattakhova
Professor Luke Vale
Professor Laura Ternent
et al. | Health-Related Quality of Life and Patient-Reported Outcome Measures in NASH-related Cirrhosis | 2020 |
|
Professor Quentin Anstee
Professor Pierre Bedossa
Professor Arun Sanyal
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial | 2019 |
|
Professor Arun Sanyal
Professor Quentin Anstee
Professor Pierre Bedossa
| REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis | 2019 |
|
Professor Arun Sanyal
Professor Quentin Anstee
| Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD | 2019 |
|
Professor Quentin Anstee
Professor Chris Day
Professor Arun Sanyal
| Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030 | 2018 |
|
Professor Quentin Anstee
Professor Arun Sanyal
| Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum | 2017 |
|
Professor Quentin Anstee
Professor Arun Sanyal
| ALT as a non-invasive biomarker of histological response to pharmacotherapy in NASH patients: insights from the elafibranor GOLDEN505 trial | 2016 |
|
Professor Quentin Anstee
Professor Arun Sanyal
| Improvement in NASH histological activity highly correlates with fibrosis regression | 2016 |
|
Professor Quentin Anstee
Professor Arun Sanyal
| Validation of mir-34a, mir-122 and mir-200a as bio-markers for identification of NASH patients eligible for treatment | 2016 |
|
